Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

RIPK3 in cell death and inflammation: the good, the bad, and the ugly.

Orozco S, Oberst A.

Immunol Rev. 2017 May;277(1):102-112. doi: 10.1111/imr.12536. Review.

PMID:
28462521
2.

Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-β Synthesis Induced by Lipopolysaccharide.

Saleh D, Najjar M, Zelic M, Shah S, Nogusa S, Polykratis A, Paczosa MK, Gough PJ, Bertin J, Whalen M, Fitzgerald KA, Slavov N, Pasparakis M, Balachandran S, Kelliher M, Mecsas J, Degterev A.

J Immunol. 2017 Jun 1;198(11):4435-4447. doi: 10.4049/jimmunol.1601717. Epub 2017 May 1.

PMID:
28461567
3.

RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection.

Downey J, Pernet E, Coulombe F, Allard B, Meunier I, Jaworska J, Qureshi S, Vinh DC, Martin JG, Joubert P, Divangahi M.

PLoS Pathog. 2017 Apr 14;13(4):e1006326. doi: 10.1371/journal.ppat.1006326. eCollection 2017 Apr.

4.

MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Hsu AC, Dua K, Starkey MR, Haw TJ, Nair PM, Nichol K, Zammit N, Grey ST, Baines KJ, Foster PS, Hansbro PM, Wark PA.

JCI Insight. 2017 Apr 6;2(7):e90443. doi: 10.1172/jci.insight.90443.

5.

Programmed cell death as a defence against infection.

Jorgensen I, Rayamajhi M, Miao EA.

Nat Rev Immunol. 2017 Mar;17(3):151-164. doi: 10.1038/nri.2016.147. Epub 2017 Jan 31. Review.

PMID:
28138137
6.

Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling.

Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH.

J Immunol Res. 2016;2016:4368101. doi: 10.1155/2016/4368101. Epub 2016 Dec 27. Review.

7.

Double-stranded RNA upregulates the expression of inflammatory mediators in human aortic valve cells through the TLR3-TRIF-noncanonical NF-κB pathway.

Zhan Q, Song R, Li F, Ao L, Zeng Q, Xu D, Fullerton DA, Meng X.

Am J Physiol Cell Physiol. 2017 Apr 1;312(4):C407-C417. doi: 10.1152/ajpcell.00230.2016. Epub 2017 Jan 4.

PMID:
28052863
8.

Viral Evasion Strategies in Type I IFN Signaling - A Summary of Recent Developments.

Schulz KS, Mossman KL.

Front Immunol. 2016 Nov 11;7:498. eCollection 2016. Review.

9.

--LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation.

Zinngrebe J, Rieser E, Taraborrelli L, Peltzer N, Hartwig T, Ren H, Kovács I, Endres C, Draber P, Darding M, von Karstedt S, Lemke J, Dome B, Bergmann M, Ferguson BJ, Walczak H.

J Exp Med. 2016 Nov 14;213(12):2671-2689. Epub 2016 Oct 24.

10.

STING Requires the Adaptor TRIF to Trigger Innate Immune Responses to Microbial Infection.

Wang X, Majumdar T, Kessler P, Ozhegov E, Zhang Y, Chattopadhyay S, Barik S, Sen GC.

Cell Host Microbe. 2016 Sep 14;20(3):329-341. doi: 10.1016/j.chom.2016.08.002.

PMID:
27631700
11.

Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase.

Berger SB, Harris P, Nagilla R, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, Capriotti C, Ouellette M, King BW, Wisnoski D, Cox J, Reilly M, Marquis RW, Bertin J, Gough PJ.

Cell Death Discov. 2015 Jul 27;1:15009. doi: 10.1038/cddiscovery.2015.9. eCollection 2015.

12.

RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4.

Najjar M, Saleh D, Zelic M, Nogusa S, Shah S, Tai A, Finger JN, Polykratis A, Gough PJ, Bertin J, Whalen MJ, Pasparakis M, Balachandran S, Kelliher M, Poltorak A, Degterev A.

Immunity. 2016 Jul 19;45(1):46-59. doi: 10.1016/j.immuni.2016.06.007. Epub 2016 Jul 5.

PMID:
27396959
13.

Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?

Rousseau S, Martel G.

Front Cell Dev Biol. 2016 May 26;4:50. doi: 10.3389/fcell.2016.00050. eCollection 2016.

14.

The ORF3 Protein of Genotype 1 Hepatitis E Virus Suppresses TLR3-induced NF-κB Signaling via TRADD and RIP1.

He M, Wang M, Huang Y, Peng W, Zheng Z, Xia N, Xu J, Tian D.

Sci Rep. 2016 Jun 8;6:27597. doi: 10.1038/srep27597.

15.

CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN.

Legarda D, Justus SJ, Ang RL, Rikhi N, Li W, Moran TM, Zhang J, Mizoguchi E, Zelic M, Kelliher MA, Blander JM, Ting AT.

Cell Rep. 2016 Jun 14;15(11):2449-61. doi: 10.1016/j.celrep.2016.05.032. Epub 2016 Jun 2.

16.

K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.

Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S.

Cell Death Differ. 2016 Oct;23(10):1628-37. doi: 10.1038/cdd.2016.51. Epub 2016 Jun 3.

PMID:
27258786
17.

The emerging role of Toll-like receptor 4 in myocardial inflammation.

Yang Y, Lv J, Jiang S, Ma Z, Wang D, Hu W, Deng C, Fan C, Di S, Sun Y, Yi W.

Cell Death Dis. 2016 May 26;7:e2234. doi: 10.1038/cddis.2016.140. Review.

18.

Necroptosis-independent signaling by the RIP kinases in inflammation.

Moriwaki K, Chan FK.

Cell Mol Life Sci. 2016 Jun;73(11-12):2325-34. doi: 10.1007/s00018-016-2203-4. Epub 2016 Apr 5. Review.

19.

Synergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway.

Hu Y, Cong X, Chen L, Qi J, Wu X, Zhou M, Yoo D, Li F, Sun W, Wu J, Zhao X, Chen Z, Yu J, Du Y, Wang J.

Sci Rep. 2016 Apr 5;6:23977. doi: 10.1038/srep23977.

20.

Ubiquitin signaling in immune responses.

Hu H, Sun SC.

Cell Res. 2016 Apr;26(4):457-83. doi: 10.1038/cr.2016.40. Epub 2016 Mar 25. Review.

Supplemental Content

Support Center